Oryzon announced the launch of its HOPE-2 clinical trial in the EU today. The trial will test the safety and efficacy of its drug, vafidemstat, in treating PMS. The company also voiced support for and sponsorship of CureSHANK’s first-ever burden of illness study. Get the full story here:
Oryzon announces hope-2 clinical trial; sponsorship of pms boi
Previous
Previous
CURESHANK COMMUNITY NEWS: OCTOBER 2025
Next
Next